// Account brief

Amgen

Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source. The brief covers Amgen as a whole company, including deCODE genetics, a wholly owned subsidiary that is not separately listed.

Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.

Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.

Scores

Theme Priority (1 to 10) Delivery (0 to 10) Stage Commitments made public, last 12 months R&D roles open on 6 Oct 2026
AI in drug discovery 6 4 live 2 21
Research labs and data 6 4 live 1 14

The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.

Summary

Amgen says it is putting AI at the heart of drug discovery, and from June 2026 one executive vice president covers R&D, AI and data. Both themes score 6 out of 10 for priority and 4 for delivery, with work shown live: AI platforms that identify targets, design proteins and predict how candidates will perform, and a loop in which AI designs proteins and robots make and test them at scale. In the last 12 months Amgen made two commitments public: the $125 million South San Francisco small-molecule discovery labs, which combine automation, robotics and data science and count under both themes, and the new combined R&D, AI and data executive role; we identified none in the year before. On 6 October 2026 it had 21 open R&D roles in AI in drug discovery and 14 in research labs and data, including agentic AI leads and a LIMS software engineer.

AI in drug discovery

What the company says: Priority 6

Putting AI at the Heart of Drug Discovery ... Amgen is working toward using artificial intelligence and machine learning to shorten that timeline and raise the odds of success.

Amgen 2025 Annual Report: Letter to Shareholders and Form 10-K, 18 Mar 2026, p. 4

making the following changes effective June 1, 2026 ... will serve as executive vice president, Research and Development, Artificial Intelligence and Data.

Amgen Announces Retirement of David M. Reese, EVP and Chief Technology Officer (organizational changes), 22 Apr 2026

highlights the company's continued investment in scientific research, artificial intelligence in drug discovery, and advanced manufacturing.

Amgen Ranks #4 on Forbes' Most Innovative Large Companies List, 22 Sep 2026

What it shows running: Delivery 4, live

Amgen has developed an integrated ... generative loop, where AI and automation continuously refine each other.

Bio Meets Tech: How Amgen is Designing the Medicines of Tomorrow, 2 Dec 2025

Amgen's AI platforms help identify genetically validated targets, generate novel proteins and predict how drug candidates will perform before they reach the lab.

Amgen 2025 Annual Report: Letter to Shareholders and Form 10-K, 18 Mar 2026, p. 4

Head's team applies protein and chemistry language models and other AI-enabled design approaches to drug discovery

Amgen's Approach to AI-Enabled Clinical Development, 20 May 2026

In Analyze, scientists review the data, apply modeling and machine learning where appropriate, and decide what to design next

Inside Amgen's Next-Generation Labs: Powering Faster, Smarter Small Molecule Drug Discovery, 6 May 2026

We're using artificial intelligence to guide us to new insights and new targets to prevent disease.

Amgen Leaders Discuss the Future of Health at Milken 2026, 18 May 2026

This loop has already tripled the speed of protein engineering and cut discovery timelines in half.

Bio Meets Tech: How Amgen is Designing the Medicines of Tomorrow, 2 Dec 2025

Amgen researchers developed a machine learning model that predicts viscosity ... with approximately 80% accuracy in internal evaluations.

Bio Meets Tech: How Amgen is Designing the Medicines of Tomorrow, 2 Dec 2025

Commitments made public in the last 12 months: 2

Commitments made public in the year before: 0

None identified in the reviewed sources.

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 21

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Technology named in these postings

Asked for as experience: Docker, AWS, Hugging Face, Databricks, MLflow, Kubernetes.

A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.

Research labs and data

What the company says: Priority 6

Marti Head, Associate Vice President, Automation, Research Data Systems, Informatics, and AI

Amgen's Approach to AI-Enabled Clinical Development, 20 May 2026

$125M investment expands Amgen's South San Francisco research hub ... Integrated labs bring medicinal chemistry, biology, protein sciences, automation, and data science together to accelerate discovery

Inside Amgen's Next-Generation Labs: Powering Faster, Smarter Small Molecule Drug Discovery, 6 May 2026

the labs are purpose-built to support more than 100 scientists and equipped with advanced technologies ... from high-throughput automation and robotics to state-of-the-art analytical tools

Inside Amgen's Next-Generation Labs: Powering Faster, Smarter Small Molecule Drug Discovery, 6 May 2026

Amgen is investing in that direction through initiatives such as the recent South San Francisco lab expansion

How AI Is Changing Drug Discovery and What It Will Take to Unlock Its Full Potential, 9 Jul 2026

What it shows running: Delivery 4, live

the labs are purpose-built to support more than 100 scientists and equipped with advanced technologies ... from high-throughput automation and robotics to state-of-the-art analytical tools

Inside Amgen's Next-Generation Labs: Powering Faster, Smarter Small Molecule Drug Discovery, 6 May 2026

AI designs proteins with desired properties. Robots make and test them at scale. Results feed back into the AI model, improving its predictions.

Bio Meets Tech: How Amgen is Designing the Medicines of Tomorrow, 2 Dec 2025

High-throughput automation further minimizes bottlenecks, scales operations efficiently and helps Amgen bring more potential therapeutics forward faster.

Bio Meets Tech: How Amgen is Designing the Medicines of Tomorrow, 2 Dec 2025

This integration improves both the speed and quality of learning.

Inside Amgen's Next-Generation Labs: Powering Faster, Smarter Small Molecule Drug Discovery, 6 May 2026

Commitments made public in the last 12 months: 1

Commitments made public in the year before: 0

None identified in the reviewed sources.

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 14

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Technology named in these postings

Named as in use: Research Controlled Vocabulary Foundation (Amgen internal platform).

Asked for as experience: AWS, Databricks, MLflow, Git, Signals, Docker.

A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.

Two questions to investigate (Ortent's interpretation)

  1. Lab systems and research data roles sit in several Amgen units, including a Biological Studies LIMS team, discovery informatics, the Research Data Enablement Hub and an automation and research data systems group, and Process Development hires for similar roles. Who decides on LIMS, ELN and data platform choices, including for the new South San Francisco labs?
  2. From June 2026 one executive holds a combined R&D, AI and data remit, separate from the Chief Technology Officer, and an AI Governance Council oversees third-party AI services. Who decides whether to buy an outside AI discovery tool or compute rather than build in-house, does the council review discovery tools, and how is this funded?

Coverage limits

Amgen's investor site blocked access, so results slides, webcasts and call transcripts were not read, and the Amgen Ventures site could not be reached. The SEC site also blocked access, so 10-K text came from annual report PDFs on amgen.com and its publication dates are uncertain. Business Wire, GlobeNewswire and several trade sites were blocked, and the amgen.com sitemap missed at least two Indian press releases, so some announcements may be missing. The press archive, annual reports and consortium sources were searched in full.

// GET IN TOUCH

Clarity when it counts.

For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.

Request a 30-minute intro call